返回
Alphamab Oncology（09966.HK）價格
09966.HK 股價走勢圖
ALPHAMAB-B (09966.HK)
Alphamab Oncology
HK$10.2
-0.77%
$-0.08
休市： Jan 16, 16:00:00 HKT
暫無資料Follow-Up Questions
Alphamab Oncology 的關鍵財務報表是什麼？
09966.HK 的關鍵財務比率是什麼？
Alphamab Oncology 的收入按細分市場或地理位置如何劃分？
Alphamab Oncology 是否盈利？
Alphamab Oncology 有負債嗎？
Alphamab Oncology 的流通股有多少？
關鍵數據
前收市價
$10.28
開盤價
$10.28
當日範圍
$9.87 - $10.4
52週區間
$3.05 - $15.75
交易量
1.4M
平均成交量
2.5M
每股盈餘 (TTM)
0.27
股息收益率
--
市值
$9.8B
什麼是 ALPHAMAB-B？
Alphamab Oncology is an investment holding company. The company is headquartered in Suzhou, Jiangsu and currently employs 484 full-time employees. The company went IPO on 2019-12-12. The Company’s in-house pipeline consists of antibody-drug conjugates (ADCs), monoclonal antibodies and bispecific antibodies in staggered development status in oncology. The Company’s product pipeline includes KN046 (PD-L1/CTLA-4 bispecific antibody), KN026 (HER2/HER2 bispecific antibody), KN035 (SubQ PD-L1), JSKN003 (HER2 biparatopic ADC), JSKN016(HER3/TROP2 bispecific antibody ADC), JSKN033(subcutaneous co-formulation of JSKN003 and KN035), used for indications such as 1L sq NSCLC, 1L HER2+ BC, 1L biliary track cancer, advanced solid tumors, HER2-expressing solid tumors and others.